<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed flow cytometric analysis of CD34+ cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in 59 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) secondary to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) using annexin V-<z:chebi fb="0" ids="37926">FITC</z:chebi>, which binds to exposed phosphatidylserine on apoptotic cells </plain></SENT>
<SENT sid="1" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was significantly increased in FAB subtypes RA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (&lt;10% blasts) (56.5% (15.1-86.5%)) compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls (18.5% (3.4-33.4%), P&lt;0.0001) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (16% (2.1-43.2%), P&lt;0.0001) </plain></SENT>
<SENT sid="2" pm="."><plain>There was no correlation between % <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, Full blood count or cytogenetics in any disease category </plain></SENT>
<SENT sid="3" pm="."><plain>Two-colour cytometric analysis of permeabilized CD34+ cells stained with antibodies to Bcl-2, Bcl-X (anti-apoptotic), Bax and Bad (pro-apoptotic), demonstrated significantly higher ratios of pro- v anti-apoptotic proteins in early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (2.47 (1.19-9.42) compared to advanced disease (1.14 (0.06-3.32), P=0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl-2-related proteins differed significantly according to disease subtype (P&lt;0.0005) </plain></SENT>
<SENT sid="5" pm="."><plain>Our results confirm that CD34+ cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was significantly increased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> and fell with disease progression </plain></SENT>
<SENT sid="6" pm="."><plain>Early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was also associated with a significantly higher CD34+ cell pro- v anti-apoptotic Bcl-2-family-protein ratio than advanced disease </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, patterns of expression of individual Bcl-2 related proteins differed significantly between different disease categories </plain></SENT>
<SENT sid="8" pm="."><plain>However, no correlation between pro- v anti-apoptotic Bcl-2-family-protein ratios and the degree of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was observed </plain></SENT>
</text></document>